Biotechnology Jobs

• Waltham, United States
• On-site
• US$242,550 – US$404,250 pa
• Director · manages people

Senior physician leader providing medical oversight, safety monitoring and clinical data interpretation across lung cancer studies within a clinical programme team. Partners with the Senior Scientist and cross-functional matrix teams on protocol design, regulatory interactions and external scientific engagement, while mentoring Medical Directors. Requires an on-site presence at least two days a week at a GSK site in Switzerland, the UK or the US.

• Stevenage
• On-site
• US$242,550 – US$404,250 pa
• Director · manages people

Senior physician leader providing medical oversight, safety evaluation and clinical data interpretation across lung cancer studies within a clinical programme team. Partners with the Senior Scientist and cross-functional Clinical Matrix Team on protocol design, regulatory interactions and external scientific engagement, while mentoring Medical Directors. Requires deep lung cancer drug development expertise including early phase trials.

• Waltham, United States
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Drafts regulatory content for FDA, EMA, CDE, PMDA and ICH submissions, and partners with digital medicine, translational imaging, modelling and data science teams to embed quantitative approaches into asset-level decisions.

MIDD · QSP · AI/ML

• London
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Sits in the Clinical Pharmacology and Quantitative Medicine organisation, partnering with digital medicine, translational imaging, modelling and data science teams, and drafting regulatory content for FDA, EMA and ICH submissions.

MIDD · QSP · AI/ML

• Stevenage
• US$188,100 – US$313,500 pa
• Director

Lead end-to-end application of Model-Informed Drug Development across the drug development lifecycle, from first-in-human studies through filing and lifecycle management, providing clinical pharmacology strategy and evidence generation. Draft and review regulatory content for FDA, EMA, CDE, PMDA and ICH, and build cross-functional partnerships across digital medicine, translational imaging, AI/ML and biostatistics. The role sits in the newly established Clinical Pharmacology and Quantitative Medicine organisation, reporting into the Respiratory, Immunology & Inflammation Research Unit.

MIDD · QSP · AI/ML

• Durham, United States
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end application of Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Partners with digital medicine, translational imaging, modelling and biostatistics teams, and drafts regulatory content for FDA, EMA, CDE, PMDA and ICH submissions. Based in the newly formed Clinical Pharmacology and Quantitative Medicine organisation, with a strong publication and scientific leadership remit.

MIDD · QSP · AI/ML

• Baar Onyx
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and partners with digital medicine, translational imaging and modelling specialists. Reports into the Respiratory, Immunology & Inflammation Research Unit within the new CPQM organisation.

MIDD · QSP · AI/ML

• USA - Pennsylvania - Upper Providence
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and partners with digital medicine, translational imaging, biostatistics and AI/ML teams. Sits in the newly formed Clinical Pharmacology and Quantitative Medicine organisation, reporting into the Respiratory, Immunology & Inflammation Research Unit.

AI/ML · Digital Medicine · Translational Imaging +2

• Baar Onyx
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Sits in the Clinical Pharmacology and Quantitative Medicine organisation, partnering with digital medicine, translational imaging, modelling and biostatistics teams, and drafting regulatory content for FDA, EMA and ICH submissions.

MIDD · QSP · AI/ML

• USA - Pennsylvania - Upper Providence
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Designs MIDD and ClinPharm evidence strategies, drafts regulatory content for FDA, EMA, CDE, PMDA and ICH, and partners with digital medicine, translational imaging, modelling and data science teams. Sits in the newly formed Clinical Pharmacology and Quantitative Medicine organisation.

MIDD · QSP · AI/ML

• London
• Hybrid · 2 days in office
• US$340,500 – US$567,500 pa
• Senior · manages people

Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability and chairing a cross-functional matrix Medicine Development Team spanning clinical, translational, regulatory, manufacturing and commercial. Drives strategy, go/no-go decisions and lifecycle plans for novel vaccine platforms such as mRNA and neoantigen-based therapies.

mRNA · Checkpoint Inhibitors

• Waltham, United States
• Hybrid · 2 days in office
• US$340,500 – US$567,500 pa
• Director · manages people

Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability across major markets. Builds and directs a matrix Medicine Development Team spanning clinical development, immunology/biomarkers, manufacturing, regulatory, safety, medical affairs and commercial, and represents the asset to senior governance boards.

mRNA · Personalized Vaccine Manufacturing · Checkpoint Inhibitors

• Stevenage
• Hybrid · 2 days in office
• US$340,500 – US$567,500 pa
• Director · manages people

Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability. Builds and leads a matrix Medicine Development Team spanning clinical development, immunology, manufacturing, regulatory, safety, medical affairs and commercial, and sets the asset strategy within GSK's oncology R&D portfolio.

mRNA · Checkpoint Inhibitors

• Zug, Switzerland
• Hybrid · 2 days in office
• US$340,500 – US$567,500 pa
• Director · manages people

Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability across major markets. Builds and directs a matrix Medicine Development Team spanning clinical development, immunology/biomarkers, manufacturing, regulatory, safety, medical affairs and commercial, and serves as asset spokesperson to senior governance boards.

mRNA · Checkpoint Inhibitors

• Upper Providence
• Hybrid · 2 days in office
• US$340,500 – US$567,500 pa
• Director · manages people

Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability. Builds and leads a matrix Medicine Development Team spanning clinical development, immunology, manufacturing, regulatory, safety, medical affairs and commercial, and drives strategy, go/no-go decisions and lifecycle planning.

mRNA · Checkpoint Inhibitors